The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Evolving Standards of HER2-Positive Breast Cancer

Sunil Verma, MD, MSEd, FRCPC
Published Online: 11:53 AM, Fri September 5, 2014
Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses evolving standards of early stage HER2-positive breast cancer.

Clinical Pearls

  • The treatment of HER2-positive breast cancer has come a long way since the discovery that the addition of trastuzumab leads to improvement in disease-free and overall survival.
  • Moving forward, the focus should not be just on improving the endpoints of disease-free and overall survival, but also defining the patient population at the highest risk.
  • There remains a need to determine how patients can be treated better with less treatment.

    <<< Back to the 2014 Breast Cancer Symposium conference page

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.